To address the molecular characteristics of tumor-reactive T cells in AML with RUNX1::RUNX1T1, we compared the transcriptional regulon (Fig. 3A) and gene expression profile (Fig. 3B, Supplementary Table S2) between tumor-reactive T cells and bystander T cells. This evidence concerns the gene RUNX1T1 and neoplasm.